TNGX
Tango TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Successful positive clinical readouts and/or a strategic partnership/acquisition drive re-rating toward the high end of analyst dispersion; execution accelerates revenue pathway and reduces binary risk.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.4.
What can break
Analyst downgrades or consensus target cuts
Momentum
92
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.50 · Bull $26.88 · Bear $10.10
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $44.00
Why
Momentum92 · Δ7d -0.4
Value41 · Δ7d -0.1
Sentiment2 · Δ7d +1.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
92
26% active weight
Current posture
7d trendImproving
Δ7d
-0.4
Δ21d
-2.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
2
34% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
+1.5
Why this grade
Composite grade D. Momentum 92.1 / Value 41.1 / Sentiment 1.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.65B
Beta
1.75
Shares Out
162.82M
P/E (TTM) · Derived
-32.7
P/S (TTM)
18.03
P/FCF (TTM) · Derived
-24.77
Rev YoY
-100.0%
EPS YoY
-12.3%
Gross Margin
+96.3%
Op Margin
-165.9%
Net Debt
-$310M
Current Ratio
27.38
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology